The benefits of bispecific antibodies in oncology drug development
Bispecific antibodies are an emerging and promising class of targeted cancer therapies. These engine…
Making cancer research faster and more cost effective.
Delivering research biosimilars at a faster rate to allow you to iterate your experiments quicker.
At the coalface of I-O research - biosimilars, bispecifics, ADCs, in vivo antibodies and isotype controls.
Supporting you in producing the next great oncology breakthrough